Joseph P. Lucia & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Joseph P. Lucia & Associates’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-61	Closed	-$36K	–	374
2022 Q2	$36K	Hold	61	–	–	0.03%	205
2022 Q1	$43K	Buy	+61	New	+$38.6K	0.03%	201
2021 Q4	–	Sell	-61	Closed	-$37K	–	457
2021 Q3	$37K	Hold	61	–	–	0.02%	244
2021 Q2	$34K	Hold	61	–	–	0.02%	253
2021 Q1	$29K	Hold	61	–	–	0.01%	255
2020 Q4	$29K	Buy	+61	New	+$32.9K	0.02%	232
2020 Q3	–	Sell	-61	Closed	-$38K	–	375
2020 Q2	$38K	Hold	61	–	–	0.03%	190
2020 Q1	$30K	Hold	61	–	–	0.03%	201
2019 Q4	$23K	Hold	61	–	–	0.02%	232
2019 Q3	$17K	Hold	61	–	–	0.02%	260
2019 Q2	$19K	Hold	61	–	–	0.02%	251
2019 Q1	$24.5K	Buy	+61	New	+$25.1K	0.04%	160

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Joseph P. Lucia & Associates's REGN Position: Q3 2022 in Review

Joseph P. Lucia & Associates sold out of Regeneron Pharmaceuticals (REGN) in Q3 2022, closing a stake of 61 shares — an estimated $36K sold.

Joseph P. Lucia & Associates first reported a position in REGN in Q1 2019 and held it in 12 quarters. The position peaked at $43K in Q1 2022. 1,080 funds tracked by Wall St. Rank hold REGN as of Q3 2022.

Joseph P. Lucia & Associates reported no remaining Regeneron Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Joseph P. Lucia & Associates sold 61 Regeneron Pharmaceuticals shares in Q3 2022, an estimated $36K.
Joseph P. Lucia & Associates first reported a position in Regeneron Pharmaceuticals in Q1 2019 and held it in 12 quarters.
Joseph P. Lucia & Associates's Regeneron Pharmaceuticals position peaked at $43K in Q1 2022.
1,080 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2022.

Based on Joseph P. Lucia & Associates's 13F filing for Q3 2022, filed 28 Oct 2022.